Publication Name	World Journal of Gastroenterology
Manuscript ID	3395
Country	United Kingdom

Received	2013-04-27 08:18
Peer-Review Started	2013-04-27 20:46
To Make the First Decision	2013-06-09 10:03
Return for Revision	2013-06-20 19:10
Revised	2013-07-12 21:55
Second Decision	2013-07-24 16:14
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-07-25 04:13
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-12-16 11:53
Publish the Manuscript Online	2014-01-14 20:11

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Autobiography
Article Title	Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus
Manuscript Source	Invited Manuscript
All Author List	Fergus Noble, Luke Nolan, Adrian C Bateman, James P Byrne, Jamie J Kelly, Ian S Bailey, Donna M Sharland, Charlotte N Rees, Timothy J Iveson, Tim J Underwood and Andrew R Bateman
Funding Agency and Grant Number	Funding Agency Grant Number A clinical research training fellowship from Cancer Research to Noble F A Medical Research Council (United Kingdom) clinician scientist fellowship to Underwood TJ
Corresponding Author	Dr. Andrew R Bateman, Lecturer, Consultant, Clinical Oncologist, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Somers Cancer Research Building, MP824, Tremona Road, Southampton SO16 6YD, United Kingdom. a.r.bateman@soton.ac.uk
Key Words	Esophageal cancer; Gastro-esophageal cancer; Neoadjuvant; Regression
Core Tip	Predictive markers of benefit from neoadjuvant chemotherapy (NAC) in esophageal adenocarcinoma are urgently required to provide a "personalised medicine" approach: directing treatment to those most likely to benefit. Before prospective studies can be initiated, retrospective series need to be interrogated to identify likely candidate markers of a positive response. In defining a positive response attention needs to be given to both response in the primary tumour and in the lymph nodes, as a previously unidentified group of patients who appear to have a poor tumoural response to NAC (tumour regression grade 3-5) do benefit from combination therapy by nodal downstaging.
Publish Date	2014-01-14 20:11
Citation	Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, Sharland DM, Rees CN, Iveson TJ, Underwood TJ, Bateman AR. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol 2013; 19(48): 9282-9293
URL	http://www.wjgnet.com/1007-9327/full/v19/i48/9282.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i48.9282

Full Article (PDF)	WJG-19-9282.pdf
Manuscript File	3395-Review.doc
Answering Reviewers	3395-Answering reviewers.pdf
Copyright License Agreement	3395-Copyright assignment.pdf
Peer-review Report	3395-Peer review(s).pdf
Scientific Editor Work List	3395-Scientific editor work list.doc